2855238-97-8
Chemical Structure
VS1150
- CAS No.: 2855238-97-8
- Formula:C36H38Cl4N12O4
- Molecular Weight:844.58
InChIKey: MAUQMZATLHCBAF-UHFFFAOYSA-N
SMILES: O=C(C1=CN=C(NCCOCCOCCNC2=NC=C(C(NC3=NN(C4=CC=C(Cl)C(Cl)=C4)CC3)=O)C(C)=N2)N=C1C)NC5=NN(C6=CC=C(Cl)C(Cl)=C6)CC5
Biological Activity: VS1150 (Compound 11) is a BCR-ABL-targeting phosphorylation-inducing chimeric small molecule (PHICS). VS1150 significantly inhibits oncogenic kinase BCR-ABL signaling by inducing inhibitory phosphorylation at its Y253 (EC50: 69 nM), subsequently triggering cell apoptosis. VS1150 also inhibits other oncogenic ABL fusions and drug-resistant mutants like T315I. VS1150 can be used for chronic myeloid leukemia (CML) and other ABL fusion-driven cancers research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VS1150 | VS1150 (Compound 11) is a BCR-ABL-targeting phosphorylation-inducing chimeric small molecule (PHICS). VS1150 significantly inhibits oncogenic kinase BCR-ABL signaling by inducing inhibitory phosphorylation at its Y253 (EC50: 69 nM), subsequently triggering cell apoptosis. VS1150 also inhibits other oncogenic ABL fusions and drug-resistant mutants like T315I. VS1150 can be used for chronic myeloid leukemia (CML) and other ABL fusion-driven cancers research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
